Bionomics (NASDAQ:BNOX) Given “Outperform” Rating at William Blair

Bionomics (NASDAQ:BNOX)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a report released on Friday,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Bionomics in a research report on Thursday, August 1st.

Bionomics Trading Up 8.2 %

Shares of BNOX stock opened at $0.32 on Friday. Bionomics has a 12-month low of $0.18 and a 12-month high of $2.19. The business’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.64.

Institutional Investors Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC purchased a new position in shares of Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 15.90% of the company’s stock.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.